← Back to Search

Blue Light for Pneumonia

N/A
Recruiting
Led By Matthew R Rosengart, MD MPH
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All patients greater than or equal to 18 years old and undergoing 1) appendectomy for appendicitis, 2) colon resection for diverticulitis,, and 3) treatment of pneumonia.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up comparing time of randomization and at 72 hours after randomization
Awards & highlights

Study Summary

This trial found that blue light exposure was able to modulate the host response to injury and critical illness, potentially improving outcome.

Who is the study for?
This trial is for adults over 18 who are undergoing surgery for appendicitis or diverticulitis, or receiving treatment for pneumonia. It's not suitable for individuals with traumatic brain injury, blindness, or those who have weakened immune systems.Check my eligibility
What is being tested?
The study tests the effects of blue light exposure on patients' inflammatory responses after surgeries like appendectomy and colon resection, and during pneumonia treatment. The control group doesn't receive blue light to compare outcomes.See study design
What are the potential side effects?
Since this trial involves exposure to blue light rather than medication, traditional side effects may not apply. However, potential discomforts could include eye strain or headache from the light.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 or older and having surgery for appendicitis, diverticulitis, or being treated for pneumonia.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~comparing time of randomization and at 72 hours after randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and comparing time of randomization and at 72 hours after randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
All Cohorts: change in serum concentrations of circulating inflammatory mediators in the blood
All groups: change in expression of circadian proteins in circulating immune cells
Pneumonia: change in bronchoalveolar lavage (BAL) bacteria concentration
Secondary outcome measures
All Cohorts: change in organ dysfunction
Appendicitis and Diverticulitis: intraabdominal abscess formation
Pneumonia: need for and duration of mechanical ventilation

Trial Design

8Treatment groups
Experimental Treatment
Active Control
Group I: Pneumonia: Blue LightExperimental Treatment1 Intervention
a 12 hours:12 hours light:dark photoperiod cycle of bright (1700 lux) blue (peak 442 nm) enriched light for a total of 3 days after the initial diagnosis and informed consent. The photoperiod is 12 hours: 0800 to 2000. At the transition from light to dark (2000), the blue-enriched light is turned off, and additional blue wavelength light removed with an amber filter.
Group II: Necrotizing Soft Tissue Infection: Blue LightExperimental Treatment1 Intervention
a 12 hours:12 hours light:dark photoperiod cycle of bright (1700 lux) blue (peak 442 nm) enriched light for a total of 3 days after the initial diagnosis and informed consent. The photoperiod is 12 hours: 0800 to 2000. At the transition from light to dark (2000), the blue-enriched light is turned off, and additional blue wavelength light removed with an amber filter.
Group III: Intraabdominal infection: Blue LightExperimental Treatment1 Intervention
a 12 hours:12 hours light:dark photoperiod cycle of bright (1700 lux) blue (peak 442 nm) enriched light for a total of 3 days after the initial diagnosis and informed consent. The photoperiod is 12 hours: 0800 to 2000. At the transition from light to dark (2000), the blue-enriched light is turned off, and additional blue wavelength light removed with an amber filter.
Group IV: Infected Joint: Blue LightExperimental Treatment1 Intervention
a 12 hours:12 hours light:dark photoperiod cycle of bright (1700 lux) blue (peak 442 nm) enriched light for a total of 3 days after the initial diagnosis and informed consent. The photoperiod is 12 hours: 0800 to 2000. At the transition from light to dark (2000), the blue-enriched light is turned off, and additional blue wavelength light removed with an amber filter.
Group V: Infected Joint: Ambient LightActive Control1 Intervention
a 12 hours:12 hours light:dark photoperiod cycle of the standard white fluorescent ambient light of the hospital for a total of 3 days after the initial diagnosis and informed consent. The photoperiod is 12 hours: 0800 to 2000. At the transition from light to dark (2000), the ambient white lights are turned off.
Group VI: Intraabdominal infection: Ambient LightActive Control1 Intervention
a 12 hours:12 hours light:dark photoperiod cycle of the standard white fluorescent ambient light of the hospital for a total of 3 days after the initial diagnosis and informed consent. The photoperiod is 12 hours: 0800 to 2000. At the transition from light to dark (2000), the ambient white lights are turned off.
Group VII: Necrotizing Soft Tissue Infection: Ambient LightActive Control1 Intervention
a 12 hours:12 hours light:dark photoperiod cycle of the standard white fluorescent ambient light of the hospital for a total of 3 days after the initial diagnosis and informed consent. The photoperiod is 12 hours: 0800 to 2000. At the transition from light to dark (2000), the ambient white lights are turned off.
Group VIII: Pneumonia: Ambient LightActive Control1 Intervention
a 12 hours:12 hours light:dark photoperiod cycle of the standard white fluorescent ambient light of the hospital for a total of 3 days after the initial diagnosis and informed consent. The photoperiod is 12 hours: 0800 to 2000. At the transition from light to dark (2000), the ambient white lights are turned off.

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,935 Previous Clinical Trials
2,299,663 Total Patients Enrolled
11 Trials studying Pneumonia
78,083 Patients Enrolled for Pneumonia
University of PittsburghLead Sponsor
1,722 Previous Clinical Trials
16,342,792 Total Patients Enrolled
5 Trials studying Pneumonia
2,083 Patients Enrolled for Pneumonia
National Institute of General Medical Sciences (NIGMS)NIH
269 Previous Clinical Trials
248,666 Total Patients Enrolled
2 Trials studying Pneumonia
2,120 Patients Enrolled for Pneumonia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are being observed for the purposes of this experiment?

"Correct. Clinicaltrials.gov data points to this trial as actively recruiting individuals, having initially been posted on March 1st 2018 and updated most recently on the same day in 2022. 72 patients are required from one medical location alone."

Answered by AI

Are there opportunities to participate in this experiment at present?

"Affirmative. The information present on clinicaltrials.gov demonstrate that this research is currently recruiting individuals for participation. This trial, which was originally posted on March 1st 2018, has been actively seeking 72 patients from one medical centre."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
Matthew R. Rosengart 2024. "The Role of Circadian Clock Proteins in Innate and Adaptive Immunity". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03482245.
All > Appendicitis > Sepsis
~96 spots leftby Jul 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top